Merck & Co., Inc. (MRK)
| Market Cap | 315.22B +58.6% |
| Revenue (ttm) | 65.77B +2.9% |
| Net Income | 8.94B -48.8% |
| EPS | 3.58 -48.0% |
| Shares Out | 2.47B |
| PE Ratio | 35.69 |
| Forward PE | 20.82 |
| Dividend | $3.40 (2.66%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 13,064,158 |
| Open | 124.33 |
| Previous Close | 123.61 |
| Day's Range | 124.00 - 128.93 |
| 52-Week Range | 76.66 - 130.29 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 132.78 (+4.04%) |
| Earnings Date | Aug 4, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $132.78, which is an increase of 4.04% from the latest price.
News
Why Healthcare Stocks Look Like a Haven in This Market
Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.
FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind
The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including those with hereditary forms of the disease, which causes elevated levels of LDL.
Merck (MRK) Rises after FDA Clears First Oral PCSK9 Cholesterol Pill
Merck ($MRK) shares rose over 3% on Thursday after the U.S. Food and Drug Administration approved LIPFENDRA, a new once‑daily pill that sharply lowers LDL cholesterol. The stock price gain…
Merck’s Lipfendra approved by FDA for adults with hypercholesterolemia
Merck (MRK) announced the FDA has approved hypercholesterolemia – enlicitide – tablets 20 mg as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, or LDL-C, in adults…
Merck's cholesterol pill gets US FDA approval
Merck said on Thursday the U.S. FDA has approved its cholesterol pill, the first of its kind to receive the health regulator's nod, bolstering the drugmaker's efforts to diversify beyond its blockbus...
The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve
Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.
Merck Gets Approval for Powerful Cholesterol-Cutting Pill
It's the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's LIPFENDRA is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia.
Merck to present new data from research pipeline for HIV treatment, prevention
Merck (MRK) announced that new data from its research pipeline for HIV treatment and prevention will be presented at the 26th International AIDS Conference, AIDS 2026,, taking place July 26-31,…
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026.
Merck says Phase 3 KEYNOTE-C93 trial of Keytruda met primary endpoint
Merck (MRK) announced the Phase 3 KEYNOTE-C93 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, met its primary endpoint of progression-free survival for the treatment of patients with mismatch re...
Merck price target raised to $142 from $135 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Merck (MRK) to $142 from $135 and keeps an Outperform rating on the shares as part of a broader…
Merck price target raised to $140 from $135 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Merck (MRK) to $140 from $135 and keeps an Overweight rating on the shares. The firm updated the company’s pipeline…
Merck price target raised to $145 from $140 at Guggenheim
Guggenheim raised the firm’s price target on Merck (MRK) to $145 from $140 and keeps a Buy rating on the shares after updating the firm’s model ahead of the company’s…
Merck confirms FDA approves Keytruda combos with Padcev
Merck (MRK) announced the U.S. Food and Drug Administration approved KEYTRUDA and KEYTRUDA QLEX, Merck’s anti-PD-1 therapies, each in combination with Padcev, as neoadjuvant treatment and then continu...
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) a...
FDA approves Keytruda combos for certain muscle invasive bladder cancer cases
The Food and Drug Administration announced that it has approved pembrolizumab, or Keytruda, from Merck (MRK), or pembrolizumab and berahyaluronidase alfa-pmph, or Keytruda Qlex, also from Merck, each ...
Redwire appoints Paul Reichert, Niki Werkheiser as SpaceMD advisors
Redwire Corporation (RDW) has appointed Paul Reichert, former Principal Investigator at Merck Research Laboratories (MRK), and Niki Werkheiser, former Director of Technology Maturation at NASA’s Space...
Merck price target raised to $150 from $145 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Merck (MRK) to $150 from $145 and keeps an Overweight rating on the shares. The firm sees Merck’s Q2…
Merck price target raised to $150 from $135 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on Merck (MRK) to $150 from $135 and keeps a Buy rating on the shares. In a sector note on Healthcare,…
Merck terminates Phase 2 Alzheimer’s study
Merck (MRK) has terminated a Phase 2 randomized, placebo-controlled study that was intended to evaluate the efficacy and safety of MK-1167 as adjunctive therapy in participants with mild to moderate…
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4.
US House committee opens investigation into Merck, AbbVie China drug trials
The chair of the U.S. House Select Committee on China opened national security investigations into whether five drugmakers including Merck and AbbVie have been involved in clinical trials conducted i...
Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?
Merck extends its bullish breakout from a pennant pattern, supported by strong volume and higher swing lows, with technical structure pointing toward continued upside potential.
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.